What are the dosing guidelines, contraindications, and adverse effects of tizanidine for acute muscle spasm?

Tizanidine for Acute Muscle Spasm

Tizanidine is an effective centrally-acting muscle relaxant for acute muscle spasm, started at 2-4 mg orally and titrated by 2-4 mg increments every 6-8 hours as needed, up to a maximum of 36 mg daily in divided doses, but it requires careful monitoring due to significant drug interactions, hepatotoxicity risk, and dose-dependent hypotension. 1, 2

Dosing Guidelines

Initial Dosing:

• Start with 4 mg orally as a single dose 2
• Effects peak at 1-2 hours and dissipate between 3-6 hours 2
• Can repeat dosing at 6-8 hour intervals as needed 2

Titration:

• Increase gradually in 2-4 mg increments to achieve optimal effect (satisfactory muscle tone reduction at tolerated dose) 2
• Maximum three doses in 24 hours 2
• Total daily dose should not exceed 36 mg 2
• Experience with single doses exceeding 8 mg and daily doses exceeding 24 mg is limited 2

Important Dosing Consideration: Food has complex effects on tizanidine pharmacokinetics that may result in clinically significant differences when switching between fed and fasted states, potentially causing increased adverse events or altered onset of activity 2. Maintain consistent administration timing relative to meals.

Mechanism and Clinical Benefits

Tizanidine is an α2-adrenergic receptor agonist (clonidine derivative) classified as a centrally acting spasmolytic agent 1. Beyond muscle relaxation, emerging evidence shows perioperative benefits including improved postoperative pain control, decreased midazolam requirements, reduced opioid consumption, and hemodynamic stability 1.

Absolute Contraindications

Concomitant use with CYP1A2 inhibitors is contraindicated:

• Ciprofloxacin - causes significantly reduced tizanidine clearance 1, 3, 4
• Fluvoxamine - causes significantly reduced tizanidine clearance 1

These combinations can lead to severe hypotension, bradycardia, and excessive sedation due to dramatically elevated tizanidine levels 1, 4.

Populations Requiring Avoidance

Should be avoided in:

• Hepatic dysfunction - risk of hepatotoxicity 1, 2
• Renal dysfunction - altered clearance and increased sedative/hypotensive effects 1
• Elderly patients - significantly increased risk of sedation and hypotension 1

Adverse Effects

Common dose-dependent effects:

• Sedation, drowsiness, dizziness 1, 2
• Ataxia or lethargy 1
• Hypotension (two-thirds of patients on 8 mg experience 20% reduction in BP) 2
• Bradycardia 2
• Orthostatic hypotension, lightheadedness 2
• Rarely: syncope 2

Serious adverse effects:

Hepatotoxicity:

• Approximately 5% of patients develop liver function test elevations >3x upper limit of normal 2
• Most cases resolve rapidly upon discontinuation 2
• Symptomatic cases may present with nausea, vomiting, anorexia, jaundice 2
• Three deaths associated with liver failure reported in postmarketing experience 2
• Monitor aminotransferase levels during first 6 months of treatment 2

Cardiovascular:

• QT interval prolongation through IKr blockade 5
• Risk peaks 1-2 hours post-dose when hypotensive effects are maximal 2

Critical Drug Interactions

Significant interactions with other CYP1A2 inhibitors (use with extreme caution):

• Oral contraceptives 1, 3
• Acyclovir, amiodarone, verapamil 1
• Mexiletine, propafenone 1
• Cimetidine, famotidine 1

These can cause significant hypotension, bradycardia, and sedation 1.

Additive CNS depression with:

• Opiates and other CNS depressants - increased sedation risk 1

Withdrawal Risk

Abrupt discontinuation in long-term users causes withdrawal syndrome:

• Rebound tachycardia 1, 6
• Hypertension 1, 6
• Hypertonia 1
• Severe body aches 6

If discontinuation needed after long-term use, taper slowly 1. The 2021 SPAQI consensus recommends continuing tizanidine preoperatively including day of surgery to avoid withdrawal 1.

Clinical Pearls

• Titrate slowly to minimize hypotension risk - the chance of significant hypotension can be minimized by careful dose titration and monitoring for signs/symptoms before dose advancement 2
• Monitor blood pressure closely when initiating or increasing doses, particularly in first 1-3 hours post-dose 2
• Patients moving from supine to upright position are at increased risk for orthostatic effects 2
• Use caution with concurrent antihypertensive therapy 2
• High interpatient variability in plasma concentrations necessitates individualized dosing 7
• For acute muscle spasm, clinical effect is typically prompt, though may be more delayed in chronic conditions 8